Arcutis Biotherapeutics, Inc.
ARQTNasdaq
$28.49
↑ +2.7%Jul 17 close · end-of-day
Price
1Y↑ +84.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.7M
Enterprise Value
-$110.9M
P/E
—
P/S
0.0
P/B
0.0
EV/EBITDA
—
PEG
—
FCF Yield
730.3%
Dividend Yield
—
Revenue (TTM)
$415.6M
Net Income (TTM)
-$2.4M
Free Cash Flow (TTM)
$26.9M
Gross Margin
—
Operating Margin
0.8%
Net Margin
-0.6%
ROE
-1.3%
ROIC
3.4%
Debt / Equity
0.6
Net Cash
$114.6M
Return 1Y
+84.0%
Company profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of arq-154.
- CEO
- Todd F. Watanabe
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 150
- Headquarters
- California
- Website
- arcutis.com
Management & directors
- Burnett PatrickSee Remarks
- Vairavan LathaSVP Chief Financial Officer
- Matsuda MasaruSee Remarks
- Watanabe Todd FranklinSee Remarks
- Edwards Larry ToddSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
ARQT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$105.4M↑ +60.1%
Diluted EPS-$0.09↓ -55.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $3.7M | $59.6M | $196.5M | $376.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$136.6M | -$206.5M | -$301.6M | -$241.1M | -$128.4M | -$12.2M |
| Net income | -$135.7M | -$206.4M | -$311.5M | -$262.1M | -$140.0M | -$16.1M |
| Diluted EPS | -$3.80 | -$4.18 | -$5.66 | -$3.78 | -$1.16 | -$0.13 |
| Operating cash flow | -$113.0M | -$174.6M | -$257.7M | -$247.1M | -$112.2M | -$5.6M |
| Free cash flow | -$113.4M | -$175.6M | -$258.0M | -$247.5M | -$112.3M | -$6.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -8183.0% | -404.5% | -65.3% | -3.3% |
| Net margin | — | — | -8449.8% | -439.8% | -71.3% | -4.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.9M | $44.8M | $71.4M | $65.8M | $81.5M | $99.2M | $129.5M | $105.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$50.1M | -$39.1M | -$7.6M | -$24.5M | -$14.6M | $8.5M | $18.4M | -$9.1M |
| Net income | -$52.3M | -$41.5M | -$10.8M | -$25.1M | -$15.9M | $7.4M | $17.4M | -$11.3M |
| Diluted EPS | -$0.42 | -$0.33 | -$0.09 | -$0.20 | -$0.13 | $0.06 | $0.14 | -$0.09 |
| Operating cash flow | -$45.1M | -$34.7M | -$748,000.00 | -$30.4M | $324,000.00 | -$1.8M | $26.2M | $2.2M |
| Free cash flow | -$45.1M | -$34.8M | -$748,000.00 | -$31.0M | $246,000.00 | -$1.8M | $26.2M | $2.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -162.3% | -87.3% | -10.7% | -37.3% | -17.9% | 8.6% | 14.2% | -8.6% |
| Net margin | -169.6% | -92.8% | -15.1% | -38.1% | -19.5% | 7.5% | 13.4% | -10.7% |
Company news
Jul 16, 2026
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Welgus Howard G. | Sale | 4,730 | $26.91 | $127,284.30 | filing |
| 2026-07-15 | Welgus Howard G. | Option exercise | 2,255 | $8.63 | $19,460.65 | filing |
| 2026-07-15 | Welgus Howard G. | Option exercise | 1,019 | $7.51 | $7,652.69 | filing |
| 2026-07-15 | Welgus Howard G. | Option exercise | 822 | $6.52 | $5,361.33 | filing |
| 2026-07-15 | Peetz Christopher | Award | 4,315 | $0.00 | $0.00 | filing |
| 2026-06-17 | Welgus Howard G. | Sale | 635 | $25.67 | $16,300.45 | filing |
| 2026-06-15 | LIN SUE-JEAN | Sale | 4,946 | $24.38 | $120,586.94 | filing |
| 2026-06-15 | Welgus Howard G. | Sale | 4,096 | $24.41 | $99,980.49 | filing |
| 2026-06-15 | Welgus Howard G. | Option exercise | 2,255 | $8.63 | $19,460.65 | filing |
| 2026-06-15 | Welgus Howard G. | Option exercise | 1,019 | $7.51 | $7,652.69 | filing |
| 2026-06-15 | Welgus Howard G. | Option exercise | 822 | $6.52 | $5,361.33 | filing |
| 2026-06-05 | Welgus Howard G. | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-06-05 | Heron Patrick J | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-06-05 | LIN SUE-JEAN | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-06-05 | Leonard Keith R | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-06-05 | Curran Terrie | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-06-05 | Munshi Amit | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-06-05 | Gilbert Halley E | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-06-05 | Krishnamohan Neha | Award | 5,778 | $0.00 | $0.00 | filing |
| 2026-05-11 | Vairavan Latha· SVP Chief Financial Officer | Sale | 435 | $21.05 | $9,156.75 | filing |
| 2026-05-11 | Burnett Patrick· See Remarks | Sale | 222 | $21.05 | $4,673.10 | filing |
| 2026-05-04 | Matsuda Masaru· See Remarks | Sale | 7,372 | $23.27 | $171,543.49 | filing |
| 2026-05-04 | Watanabe Todd Franklin· See Remarks | Sale | 3,172 | $23.61 | $74,892.82 | filing |
| 2026-05-04 | Vairavan Latha· SVP Chief Financial Officer | Sale | 1,341 | $23.61 | $31,661.81 | filing |
| 2026-05-04 | Matsuda Masaru· See Remarks | Sale | 884 | $23.61 | $20,871.77 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.